Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA
Date : 08/08/2018 @ 8:45AM
Source : NetworkNewsWire
Stock : Potnetwork Holdings, Inc. (PC) (POTN)
Quote : 0.23965 0.0 (0.00%) @ 8:00AM
Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA
Print
Alert
CannabisNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts
Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy
CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR
What’s most transformative about this drug approval is that this is the first time the FDA — the governmental arbiter of safe and effective medicine in the United States — has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD’s mass appeal is that it’s believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body’s nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues and chronic pain. It’s being researched to treat Alzheimer’s, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.
Continued rigorous clinical research is being conducted to further confirm all the potential therapeutic benefits that may be found in this cannabinoid extract. In the meantime, the mass appeal of CBD remains unabated, and the market for CBD products continues to grow at an astounding rate. Committed to the legal hemp-derived CBD market, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers with pure, hemp plant-based CBD nutritional products through its global hempSMART™ brand and has initiated broad-ranging, innovative cultivation programs for legal, high-quality hemp. Others vying for position in the burgeoning CBD space include Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), PotNetwork Holdings, Inc. (OTC: POTN) and Medical Marijuana, Inc. (OTC: MJNA).
The Boom Has Just Begun
Date : 08/08/2018 @ 8:45AM
Source : NetworkNewsWire
Stock : Potnetwork Holdings, Inc. (PC) (POTN)
Quote : 0.23965 0.0 (0.00%) @ 8:00AM
Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA
Alert
CannabisNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts
Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy
CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR
What’s most transformative about this drug approval is that this is the first time the FDA — the governmental arbiter of safe and effective medicine in the United States — has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD’s mass appeal is that it’s believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body’s nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues and chronic pain. It’s being researched to treat Alzheimer’s, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.
Continued rigorous clinical research is being conducted to further confirm all the potential therapeutic benefits that may be found in this cannabinoid extract. In the meantime, the mass appeal of CBD remains unabated, and the market for CBD products continues to grow at an astounding rate. Committed to the legal hemp-derived CBD market, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers with pure, hemp plant-based CBD nutritional products through its global hempSMART™ brand and has initiated broad-ranging, innovative cultivation programs for legal, high-quality hemp. Others vying for position in the burgeoning CBD space include Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), PotNetwork Holdings, Inc. (OTC: POTN) and Medical Marijuana, Inc. (OTC: MJNA).
The Boom Has Just Begun
10
